7 results about "Methoxyacetic acid" patented technology

The application relates to a concentration device for methoxyacetic acid preparation and relates to the technical field of methoxyacetic acid preparation, which comprises a concentration barrel, a spraying assembly, a collecting assembly, an evaporation assembly and a detection assembly. One side top of the concentration barrel is communicated with a liquid inlet pipe, the spraying assembly is arranged in the concentration barrel, the liquid inlet pipe is communicated with the spraying assembly, and the spraying assembly is used for spraying a solution needing to be concentrated into the concentration barrel. The collecting assembly is arranged at the bottom of the concentration barrel and is used for collecting the concentrated solution. A lead screw is fixedly arranged at the center of the bottom in the concentration barrel, the lead screw is a reciprocating lead screw, the lead screw is vertically arranged and coaxially arranged with the concentration barrel. A rotating block is spirally transmission-connected with the lead screw in the vertical direction. The evaporation assembly is used for contacting steam with the sprayed solution, so that the solvent in the solution is evaporated together. The detection assembly can assist in detecting the concentrated solution. The concentration device for methoxyacetic acid preparation can realize an efficient evaporation and concentration process.

The invention belongs to the technical field of environmental protection, and relates to a preparation method of an ether-rich porous ionic liquid and desulfurization application of the ether-rich porous ionic liquid. The preparation method comprises the following steps: mixing 2-methylimidazole with a methanol solution of zinc nitrate hexahydrate, performing hydrothermal reaction, and performing centrifugal drying to obtain ZIF-8 white particles; the preparation method comprises the following steps: mixing tris (3, 6-dioxaheptyl) amine and methoxyacetic acid, reacting at normal temperature, and performing vacuum drying to obtain light yellow transparent ionic liquid [TMEA] [MOAC]; the preparation method comprises the following steps: mixing ZIF-8 with [TMEA] [MOAC], and carrying out ultrasonic oscillation and uniform dispersion at room temperature to obtain a faint yellow transparent solution ZIF-8 / [TMEA] [MOAC] porous ionic liquid. The porous ionic liquid disclosed by the invention has high specific surface area and high adsorbability of ZIF-8 and good flowability of the ionic liquid, a nano confinement space formed by an interface improves the synergistic interaction effect of multiple active sites, and the absorption performance and regeneration cycle of SOs under normal pressure are improved.

Provided herein in some embodiments are pharmaceutical compositions comprising a prostacyclin (PGI2) receptor agonist selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1) and pharmaceutically acceptable salts, solvates, and hydrates thereof, as disclosed herein. In some embodiments the pharmaceutical compositions comprise a compound selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), and pharmaceutically acceptable salts, solvates, and hydrates thereof, in an amount equivalent to a therapeutically effective amount of Compound 1, the composition having a release rate by weight of the compound in an aqueous medium that is one or more of release rates (a), (b) and (c) as disclosed herein. The compositions of the present invention are useful in the treatment of PGI2 related disorders, such as those disclosed herein.

Provided herein in some embodiments are pharmaceutical compositions comprising a prostacyclin (PGI2) receptor agonist selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1) and pharmaceutically acceptable salts, solvates, and hydrates thereof, as disclosed herein. In some embodiments the pharmaceutical compositions comprise a compound selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy) acetic acid (Compound 1), and pharmaceutically acceptable salts, solvates, and hydrates thereof, in an amount equivalent to a therapeutically effective amount of Compound 1, the composition having a release rate by weight of the compound in an aqueous medium that is one or more of release rates (a), (b) and (c) as disclosed herein. The compositions of the present invention are useful in the treatment of PGI2 related disorders, such as those disclosed herein.

The application relates to a PMI foam which comprises the following raw materials: methacrylonitrile, methacrylic acid, a toughening agent, a foaming agent, an initiator and a crosslinking agent. The PMI foam described in the application has excellent toughening performance by using modified nitrile rubber as the toughening agent, and the dissolution speed of the nitrile rubber can be greatly improved by using a mixture of ethyl-methoxyacetate and methyl-3-methoxypropionate to dissolve the modified nitrile rubber when the PMI foam is prepared.

The invention provides a synthetic preparation process of methoxyacetic acid, which comprises the following steps: mixing ethylene glycol monomethyl ether, a water solvent, an auxiliary agent and a platinum-loaded carbon catalyst in a reactor to form a reaction mixture; introducing inert gas into the reactor to replace air in the reactor; the method comprises the following steps: heating a reactor to 80-90 DEG C under a stirring condition, introducing oxidant gas, maintaining the reaction pressure at 1.0-1.5 bar, and reacting for 3-4 hours to oxidize ethylene glycol monomethyl ether to generate methoxyacetic acid; after the reaction is finished, cooling reaction liquid, and filtering and separating the platinum-loaded carbon catalyst to obtain filtrate; adding an acidifying reagent into the filtrate, and adjusting the pH value to 1.0-4.5; separating methoxyacetic acid from the acidified liquid by a crystallization method; and carrying out reduced pressure distillation or drying to obtain purified methoxyacetic acid.

The present invention relates to a herbicidal composition comprising (A) an herbicidal amount of a compound of Formula (I) (I) wherein G is selected from the group consisting of hydrogen, -C(O)CH3 and -C(O)OCH3;and (B) at least one herbicide, or an ester or salt thereof acceptable from an agrochemical point of view, selected from the group consisting of icafolin (B1) (or icafolin-methyl (B1a)), benquitrione (B2), broclozone (B3), butachlor (B4), clomazone (B5), cyclopyranyl (B6), fluchloraminopyr (B7) [or fluchloraminopyr-tefuryl pyraquinate (B9), (B7a)], fluphenoxymacyl (B8), 2-[2-[2-bromo-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy]phenoxy]-2-methyl methoxy acetate (B10), 6-chloro-4-(2,7-dimethyl-1-naphthyl)-5-hydroxy-2-methylpyridazin-3-one (B11), 3-[2-chloro 5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1(2H)pyrimidinyl]-4-fluorophenyl]-3a,4,5,6-tetrahydro-6-methyl-6aH cyclopent[d]isoxazol-6a-methylcarboxylate (B12), 2-[1 [[2-(4-chlorophenoxy)propoxy]imino]butyl]-5-[2 (ethylthio)propyl]-3-hydroxy-2-cyclohexen-1-one (B13), 2-[(2 2 5 10 15 20 25 bromo-6-fluorophenyl)methoxy]-4-isopropyl-1-methyl-7 oxabicyclo[2.2.1]heptane (B14) and diflufenican (B15).;